AKTS
Aktis Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$27.05
+1.50%Aug 13, 2026, 00:00 UTC
Aktis Oncology reported Q2 2026 collaboration revenue of $3.4 million, up from $1.6 million a year earlier, with a net loss of $24.1 million and cash and marketable securities of $517.3 million as of June 30, 2026.